resmed inc. - RMD

RMD

Close Chg Chg %
221.03 -1.59 -0.72%

Open Market

219.44

-1.59 (0.72%)

Volume: 144.64K

Last Updated:

Sep 9, 2026, 10:14 AM EDT

Company Overview: resmed inc. - RMD

RMD Key Data

Open

$220.85

Day Range

217.00 - 220.85

52 Week Range

180.27 - 284.87

Market Cap

$32.94B

Shares Outstanding

144.25M

Public Float

142.89M

Beta

0.77

Rev. Per Employee

N/A

P/E Ratio

21.89

EPS

$10.47

Yield

111.29%

Dividend

$0.66

EX-DIVIDEND DATE

Aug 20, 2026

SHORT INTEREST

N/A

AVERAGE VOLUME

1.39M

 

RMD Performance

1 Week
 
-3.20%
 
1 Month
 
4.30%
 
3 Months
 
13.49%
 
1 Year
 
-18.17%
 
5 Years
 
-25.22%
 

RMD Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 30
Full Ratings ➔

About resmed inc. - RMD

ResMed, Inc. engages in the design, manufacture, and marketing of equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, as well as the provision of software solutions for residential care providers. It operates through the following segments: Sleep and Breathing Health and Residential Care Software. The Sleep and Breathing Health segment relates primarily to the sale of therapy-based equipment. The Residential Care Software segment provides software access with ongoing support and maintenance services as well as professional services such as training and consulting. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

RMD At a Glance

ResMed, Inc.
9001 Spectrum Center Boulevard
San Diego, California 92123
Phone 1-858-836-5000 Revenue 5.65B
Industry Medical Specialties Net Income 1.52B
Sector Health Technology 2026 Sales Growth 9.854%
Fiscal Year-end 06 / 2027 Employees 11,370
View SEC Filings

RMD Valuation

P/E Current 21.894
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 18.685
Price to Sales Ratio 5.035
Price to Book Ratio 4.268
Price to Cash Flow Ratio 15.76
Enterprise Value to EBITDA 12.836
Enterprise Value to Sales 4.92
Total Debt to Enterprise Value 0.03

RMD Efficiency

Revenue/Employee 497,224.538
Income Per Employee 133,974.758
Receivables Turnover 5.211
Total Asset Turnover 0.66

RMD Liquidity

Current Ratio 3.10
Quick Ratio 2.422
Cash Ratio 1.056

RMD Profitability

Gross Margin 60.251
Operating Margin 34.014
Pretax Margin 33.951
Net Margin 26.945
Return on Assets 17.774
Return on Equity 24.269
Return on Total Capital 20.554
Return on Invested Capital 21.916

RMD Capital Structure

Total Debt to Total Equity 12.542
Total Debt to Total Capital 11.144
Total Debt to Total Assets 9.212
Long-Term Debt to Equity 8.152
Long-Term Debt to Total Capital 7.243
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Resmed Inc. - RMD

Collapse All in section
All values USD millions. 2023 2024 2025 2026 5-year trend
Sales/Revenue
4.22B 4.69B 5.15B 5.65B
Sales Growth
+18.02% +10.95% +9.84% +9.85%
Cost of Goods Sold (COGS) incl D&A
1.91B 2.08B 2.14B 2.25B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
196.52M 216.21M 235.81M 244.15M
Depreciation
117.11M 129.13M 150.22M 155.91M
Amortization of Intangibles
79.42M 87.08M 85.59M 88.25M
COGS Growth
+20.47% +8.76% +2.89% +5.17%
Gross Income
2.31B 2.61B 3.01B 3.41B
Gross Income Growth
+16.07% +12.76% +15.37% +13.18%
Gross Profit Margin
+54.79% +55.68% +58.48% +60.25%
2023 2024 2025 2026 5-year trend
SG&A Expense
1.16B 1.22B 1.32B 1.48B
Research & Development
287.64M 307.52M 331.28M 378.29M
Other SG&A
874.00M 917.14M 991.02M 1.11B
SGA Growth
+16.99% +5.42% +7.97% +12.18%
Other Operating Expense
- - - -
-
Unusual Expense
(9.13M) 54.03M (7.60M) 15.99M
EBIT after Unusual Expense
1.16B 1.33B 1.69B 1.91B
Non Operating Income/Expense
1.15M (5.24M) (4.82M) 12.46M
Non-Operating Interest Income
- - - 15.87M
-
Equity in Earnings of Affiliates
(7.26M) (1.85M) 3.64M 6.96M
Interest Expense
- 60.62M 60.05M 12.61M
Interest Expense Growth
- +171.67% -0.92% -79.00%
Gross Interest Expense
- 60.62M 60.05M 12.61M
Interest Capitalized
- - - -
-
Pretax Income
1.10B 1.26B 1.68B 1.92B
Pretax Income Growth
+14.70% +14.81% +32.64% +14.42%
Pretax Margin
+26.09% +27.00% +32.60% +33.95%
Income Tax
204.11M 243.85M 276.84M 396.12M
Income Tax - Current - Domestic
50.77M 74.35M 39.66M 60.82M
Income Tax - Current - Foreign
198.77M 219.37M 298.17M 331.43M
Income Tax - Deferred - Domestic
(24.11M) (27.55M) (6.93M) 43.05M
Income Tax - Deferred - Foreign
(21.32M) (22.33M) (54.06M) (39.17M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
(7.26M) (1.85M) 3.64M 6.96M
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
897.56M 1.02B 1.40B 1.52B
Minority Interest Expense
- - - -
-
Net Income
897.56M 1.02B 1.40B 1.52B
Net Income Growth
+15.15% +13.75% +37.20% +8.75%
Net Margin Growth
+21.25% +21.79% +27.22% +26.94%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
897.56M 1.02B 1.40B 1.52B
Preferred Dividends
- - - -
-
Net Income Available to Common
897.56M 1.02B 1.40B 1.52B
EPS (Basic)
6.1156 6.9442 9.5472 10.4677
EPS (Basic) Growth
+14.61% +13.55% +37.48% +9.64%
Basic Shares Outstanding
146.76M 147.02M 146.72M 145.52M
EPS (Diluted)
6.087 6.9194 9.5067 10.4297
EPS (Diluted) Growth
+14.83% +13.68% +37.39% +9.71%
Diluted Shares Outstanding
147.46M 147.55M 147.34M 146.05M
EBITDA
1.35B 1.60B 1.92B 2.17B
EBITDA Growth
+12.93% +18.67% +20.18% +12.68%
EBITDA Margin
+31.93% +34.16% +37.37% +38.33%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 261.476
Number of Ratings 30 Current Quarters Estimate 2.688
FY Report Date 09 / 2026 Current Year's Estimate 12.094
Last Quarter’s Earnings 2.95 Median PE on CY Estimate N/A
Year Ago Earnings 11.17 Next Fiscal Year Estimate 13.30
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 17 16 26 26
Mean Estimate 2.69 3.04 12.09 13.30
High Estimates 2.78 3.11 12.20 13.90
Low Estimate 2.60 3.00 11.82 12.59
Coefficient of Variance 2.01 1.23 0.73 2.37

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 13 13 15
OVERWEIGHT 4 4 5
HOLD 10 10 8
UNDERWEIGHT 2 2 1
SELL 1 1 1
MEAN Overweight Overweight Overweight

Insider Actions for Resmed Inc. - RMD

Date Name Shares Transaction Value
Jun 10, 2026 Michael J. Farrell Chairman and CEO; Director 471,214 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $146.34 per share 68,957,456.76
Jun 10, 2026 Michael J. Farrell Chairman and CEO; Director 466,256 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $193.96 per share 90,435,013.76
Jun 10, 2026 Michael J. Farrell Chairman and CEO; Director 24,957 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2026 Peter C. Farrell Director 62,773 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $260.22 per share 16,334,790.06
Nov 25, 2025 Nicole Mowad-Nassar Director 777 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 25, 2025 John B. Hernandez Director 5,118 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Resmed Inc. in the News